MetCura Pharmaceuticals AUS

MetCura is an Australian biotechnology company focused on developing first-in-class small molecule therapeutics that target the metabolic vulnerabilities of cancer cells. The company's primary strategy involves inhibiting monocarboxylate transporters (MCT1 and MCT4) to disrupt the lactate transport mechanism essential for the survival and metastasis of glycolytic tumors. By blocking these pathways, MetCura aims to starve cancer cells of energy and prevent the acidification of the tumor microenvironment, thereby enhancing the efficacy of existing treatments and overcoming drug resistance. Their lead programs are currently in the pre-clinical stage, targeting high-need indications such as metastatic breast and pancreatic cancers.